A Phase 1 interventional study of vorinostat in Lymphoma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2015-04-21.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 20 studies testing vorinostat in Lymphoma — none open to participants now, 1 under way, 1 of them phase 3. Vorinostat · Lymphoma.
Among the 20 studies testing vorinostat in Lymphoma, this one is the 13th largest by enrollment of the 19 interventional ones that give a count, is one of 3 that started in 2008, is one of 7 in phase 1, and was the 6th registered.
3,018 studies on the registry are indexed under Lymphoma; 433 are open to participants now.
Browse Lymphoma studies →None of the 20 studies testing vorinostat in Lymphoma is open now. The open studies under Lymphoma, anywhere →
Vorinostat: first FDA approval 2006 (ZOLINZA). What it is approved for, and how studies give it, is on its page →
Of the 346 Lymphoma studies recruiting now, 227 (66%) set no upper age limit and 78 (23%) stop at 75 or younger; 77 take children under 18; 20 take healthy volunteers.
This study: 20 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
20 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 13 · Phase 2 12 · Phase 3 2
First in 2000; this study’s year is marked. 3 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 10 is below the median of 43 across 2,319 interventional studies indexed under Lymphoma.
Median enrollment 17 across the 19 interventional studies. Of the 18 that completed or were terminated, 12 (67%) have results posted.
This tab as a report to print or save as PDF → With an account.
4 of 20 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 503 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
17 studies in Lymphoma by Merck & Co., Inc: 2 open now, 4 under way, none of them phase 3. Of 13 finished, 5 (38%) have results posted.
Among the 17 studies in Lymphoma by Merck & Co., Inc, this one is the 16th largest by enrollment, is one of 2 that started in 2008, is one of 11 in phase 1, and was the 7th registered.
Merck & Co., Inc’s Lymphoma studies by the year they started, since 2003.
None of the studies under way reaches primary completion within a year.
Among the 20 studies testing vorinostat in Lymphoma, from their registry updates:
Nothing recorded among them since 2026-09-25.
Among Merck & Co., Inc’s 17 in Lymphoma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Part I evaluates the safety, tolerability and pharmacokinetics (PK) of vorinostat in Japanese patients with relapsed or refractory CTCL. Part II evaluates the safety of vorinostat in Japanese pts. with relapsed or refractory CTCL. Relapsed or refractory CTCL patients will be newly enrolled in Part II.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria (Parts I \& II):
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: vorinostat
Parts I \& II: Vorinostat (400 mg) Oral, daily (QD). Treatment period is 28 days per cycle.
Also known as: MK-0683, Zolinza
Parts I & II: Number of Participants Experiencing Clinical or Laboratory Adverse Experiences (AE)
A laboratory AE is defined as any unfavorable \& unintended change in the chemistry of the body temporally associated with the use of study product, whether or not considered related to the use of the product. A clinical AE is defined similarly but also includes changes in structure or function of the body.
Time frame: Day 1 up until 30 days post study completion or early termination (up to approximately 506 days)
Part I: Number of Participants Experiencing Dose Limiting Toxicity (DLT)
A DLT was defined as any of the following (per Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0): * Grade 3 (severe)-4 (life-threatening) neutropenia with fever ≥ 38.5ºC * Grade 3-4 neutropenia with an infection requiring antibiotic or antifungal treatment * Grade 4 neutropenia lasting at least 5 days * Grade 4 thrombocytopenia * Other Grade 4 hematologic toxicity, including a decrease in hemoglobin, only at the discretion of the principal investigator * Grade 3 or 4 non-hematologic event, except which are manageable by supportive care or non-prohibited therapies
Time frame: Day 1 to Day 28
Part I: Total Drug Exposure (Area Under the Concentration Curve, AUC[0-24 Hours])
Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.
Time frame: Days 1 & 28 of Cycle 1
Part I: Maximum Drug Concentration (Cmax)
Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.
Time frame: Days 1 & 28 of Cycle 1
Part I: Time at Which Cmax Occurs (Tmax)
Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.
Time frame: Days 1 & 28 of Cycle 1
Part I: The Amount of Time it Takes for the Drug Concentration to Decrease by Half (T1/2)
Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.
Time frame: Days 1 & 28 of Cycle 1
| Milestone | Part I | Part II |
|---|---|---|
| Started | 6 | 4 |
| Completed | 0 | 0 |
| Not completed | 6 | 4 |
| Withdrew: Physician decision | 2 | 3 |
| Withdrew: Progressive disease | 3 | 1 |
| Withdrew: Protocol violation | 1 | 0 |
A laboratory AE is defined as any unfavorable \& unintended change in the chemistry of the body temporally associated with the use of study product, whether or not considered related to the use of the product. A clinical AE is defined similarly but also includes changes in structure or function of the body.
| participants | Vorinostat |
|---|---|
| Clinical AEs | 10 |
| Laboratory AEs | 6 |
Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.
| µM*hr | Vorinostat |
|---|---|
| Day 1 (n=6) | 4.59 ± 2.34 |
| Day 28 (n=5) | 5.59 ± 1.24 |
A DLT was defined as any of the following (per Common Terminology Criteria for Adverse Events \[CTCAE\] version 3.0): * Grade 3 (severe)-4 (life-threatening) neutropenia with fever ≥ 38.5ºC * Grade 3-4 neutropenia with an infection requiring antibiotic or antifungal treatment * Grade 4 neutropenia lasting at least 5 days * Grade 4 thrombocytopenia * Other Grade 4 hematologic toxicity, including a decrease in hemoglobin, only at the discretion of the principal investigator * Grade 3 or 4 non-hematologic event, except which are manageable by supportive care or non-prohibited therapies
| participants | Vorinostat |
|---|---|
| Part I: Number of Participants Experiencing Dose Limiting Toxicity (DLT) | 1 |
Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.
| µM | Vorinostat |
|---|---|
| Day 1 (n=6) | 0.83 ± 0.37 |
| Day 28 (n=5) | 1.17 ± 0.37 |
Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.
| hours | Vorinostat |
|---|---|
| Day 1 (n=6) | 2.91 (2.00 to 6.00) |
| Day 28 (n=5) | 3.73 (2.93 to 4.28) |
Blood samples taken as follows: Day 1 \& Day 28 of Cycle 1: pre dose, and 0.25, 0.5, 1.0, 1.5, 2.0, 3.0, 4.0, 6.0, 8.0, 10, 12 and 24 hours after dosing of vorinostat.
| hours | Vorinostat |
|---|---|
| Day 1 (n=5) | 1.94 ± 1.30 |
| Day 28 (n=4) | 2.30 ± 1.10 |
Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Vorinostat | — | 3/10 (30%) | 10/10 (100%) |
| Event | Vorinostat |
|---|---|
| InfectionInfections and infestations | 2/10 |
| NauseaGastrointestinal disorders | 1/10 |
| VomitingGastrointestinal disorders | 1/10 |
| Cellulitis streptococcalInfections and infestations | 1/10 |
| Event | Vorinostat |
|---|---|
| ThrombocytopeniaBlood and lymphatic system disorders | 8/10 |
| NauseaGastrointestinal disorders | 6/10 |
| AnorexiaMetabolism and nutrition disorders | 6/10 |
| MalaiseGeneral disorders | 5/10 |
| HypoalbuminaemiaMetabolism and nutrition disorders | 5/10 |
| DiarrhoeaGastrointestinal disorders | 4/10 |
| VomitingGastrointestinal disorders | 4/10 |
| FatigueGeneral disorders | 4/10 |
| PyrexiaGeneral disorders | 4/10 |
| HypermagnesaemiaMetabolism and nutrition disorders | 4/10 |
| Age, Continuous(years) | Vorinostat |
|---|---|
| Mean | 55.5 ± 12.0 |
| Sex: Female, Male(Participants) | Vorinostat |
|---|---|
| Female | 2 |
| Male | 8 |
| Region of Enrollment(participants) | Vorinostat |
|---|---|
| Japan | 10 |
No study locations are listed for this record.
The record gives a start of Aug 2008, a primary completion of Jul 2011 and a completion of Jul 2011. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2012, 1 year after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Vorinostat